Close Menu

Scienion

Boston-based Cellink will acquire the German firm for €40 million in cash and 2,814,032 newly issued shares valued at €40 million at a price of SEK 146.6 per share.

The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.

The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

The partners will develop multiplex tests to detect human pathogens in 75 minutes on Grenier's PCR-based Genspeed Test System.

The partners will launch the alliance by developing a colorimetric reader system for multiplexed lateral flow microarrays.

The partners will combine the sciFlexarrayer with Anteo's reagents to improve the functionality and shelf-life of activated glass and polymer slides and other arrays.

QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.

NEW YORK (GenomeWeb) — Scienion and Genomica today announced the CE IVD marking and launch of their jointly developed multiplex molecular assay for sexually transmitted infections.

NEW YORK (GenomeWeb) – The Institute for Global Food Security, MBio Diagnostics, and Scienion today announced they will combine their technologies to create tools to monitor marine toxins.

NEW YORK (GenomeWeb) – The AIT Austrian Institute of Technology, BioVendor, and Scienion announced today a partnership to develop an in vitro diagnostic test for the early detection of colon cancer.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.